SCHEMBL7085913

SCHEMBL7085913

Oc1c(Br)cc2[nH]c3cnccc3c2c1Br

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 1.00
ADORA2A P29274 1/20 1.00
ADORA1 P30542 1/20 1.00
CHUK O15111 8/20 0.52
PRKD3 O94806 1/20 0.52
PRKCG P05129 1/20 0.52
PRKCB P05771 1/20 0.52
PRKCA P17252 1/20 0.52
CSNK2A2 P19784 1/20 0.52
PRKCH P24723 1/20 0.52
PRKCI P41743 1/20 0.52
CSNK2B P67870 1/20 0.52
CSNK2A1 P68400 1/20 0.52
PRKCE Q02156 1/20 0.52
PRKCQ Q04759 1/20 0.52
PRKCZ Q05513 1/20 0.52
PRKCD Q05655 1/20 0.52
PRKD1 Q15139 1/20 0.52
KDM5A P29375 4/20 0.45
IKBKB O14920 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10486739 0.78 ADORA3 (0.64) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL19974114 0.77 ADORA3 (0.62) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL7083125 0.76 ADORA3 (0.61) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL7082459 0.73 ADORA3 (0.57) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL7078407 0.73 ADORA3 (0.57) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL31060553 0.73 ADORA3 (1.00) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL12396541 0.70 CHUK (0.78) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL30322777 0.70 CHUK (0.78) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL14330620 0.70 ADORA3 (0.53) ADORA3ADORA2AADORA1CHUKPRKD3
SCHEMBL3191588 0.69 CHUK (0.65) ADORA3ADORA2AADORA1CHUKKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030148259-A1 Method of identifying insulin secretion stimulating compounds, and the use of such compounds in treating insulin-secretion related disorders KAROLINSKA INNOVATIONS AB (SE) 2003-08-07 US claimed
WO-2003065036-A1 METHOD OF IDENTIFYING INSULIN SECRETION STIMULATING COMPOUNDS, AND THE USE OF SUCH COMPOUNDS IN TREATING INSULIN-SECRETION RELATED DISORDERS KAROLINSKA INNOVATIONS AB (SE) 2003-08-07 WO claimed
JP-1197482-A None JP disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-8551694-B2 Isolation and use of ryanodine receptors E I DU PONT DE NEMOURS AND COMPANY (US) 2013-10-08 US disclosed
US-8551694-B2 Isolation and use of ryanodine receptors E I DU PONT DE NEMOURS AND COMPANY (US) 2013-10-08 US disclosed
US-20120276554-A1 ISOLATION AND USE OF RYANODINE RECEPTORS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-11-01 US disclosed
US-20120276554-A1 ISOLATION AND USE OF RYANODINE RECEPTORS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-11-01 US disclosed
US-8101715-B2 Ryanodine receptor polypeptides E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-01-24 US disclosed
US-8101715-B2 Ryanodine receptor polypeptides E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-01-24 US disclosed
US-7498408-B2 Ryanodine receptor polypeptides E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-03-03 US disclosed
US-7498408-B2 Ryanodine receptor polypeptides E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-03-03 US disclosed
US-20070161037-A1 Isolation and use of ryanodine receptors GUTTERIDGE STEVEN 2007-07-12 US disclosed
US-20070161037-A1 Isolation and use of ryanodine receptors GUTTERIDGE STEVEN 2007-07-12 US disclosed
US-20070105098-A1 Isolation and use of ryanodine receptors E. I. DU PONT DE NEMOURS AND COMPANY 2007-05-10 US disclosed
US-20070105098-A1 Isolation and use of ryanodine receptors E. I. DU PONT DE NEMOURS AND COMPANY 2007-05-10 US disclosed
US-7205147-B2 Nucleic acids encoding ryanodine receptors E.I. DU PONT DE NEMOURS AND COMPANY (US) 2007-04-17 US disclosed
US-20030148259-A1 Method of identifying insulin secretion stimulating compounds, and the use of such compounds in treating insulin-secretion related disorders KAROLINSKA INNOVATIONS AB (SE) 2003-08-07 US disclosed
JP-H01197482-A BROMINE-CONTAINING INDOLE MITSUBISHI KASEI CORP 1989-08-09 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161037-A1 Isolation and use of ryanodine receptors RYR1, RYR2, CHERP ADORA3 1707/4885ADORA2A 2507/4885ADORA1 2869/4885
US-20120276554-A1 ISOLATION AND USE OF RYANODINE RECEPTORS RYR1, RYR2, CACYBP ADORA3 3058/4885ADORA2A 2997/4885ADORA1 3283/4885
US-20070105098-A1 Isolation and use of ryanodine receptors RYR1, RYR2, CHERP ADORA3 1679/4885ADORA2A 2344/4885ADORA1 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.